Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update

Evoke Pharma, Inc. (NASDAQ:EVOK) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 31,200 shares, a decrease of 28.9% from the February 13th total of 43,900 shares. Currently, 2.2% of the company’s stock are sold short. Based on an average trading volume of 18,400 shares, the days-to-cover ratio is currently 1.7 days.

Evoke Pharma Trading Down 0.8 %

Shares of EVOK stock traded down $0.03 on Friday, reaching $3.82. 25,287 shares of the stock were exchanged, compared to its average volume of 11,261. The business’s 50 day moving average price is $4.53 and its 200 day moving average price is $4.71. The company has a market capitalization of $5.68 million, a price-to-earnings ratio of -0.35 and a beta of 0.12. Evoke Pharma has a twelve month low of $3.44 and a twelve month high of $12.32.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). The firm had revenue of $3.31 million for the quarter, compared to analyst estimates of $3.08 million. Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Evoke Pharma in a research report on Wednesday. They set a “sell” rating on the stock.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC raised its stake in Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,194 shares of the specialty pharmaceutical company’s stock after acquiring an additional 91,945 shares during the period. Nantahala Capital Management LLC owned 9.95% of Evoke Pharma worth $655,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.